Western blot of HEK293 lysate showing specific immunolabeling of the ~160 kDa MerTK phosphorylated at Tyr749/753/754 in the first lane (-). Phosphospecificity is shown in the second lane (+) where the immunolabeling is completely eliminated by blot treatment with lambda phosphatase (λ-Ptase, 1200 units for 60 minutes).
Anti-MerTK Tyr749/753/754 Antibody
Along with Tyro-3 and Axl, Mer is a member of the TAM family of receptor tyrosine kinases (RTKs). The TAM family of RTKs regulates cell proliferation/survival, cell adhesion and migration, and blood clot stabilization processes, along with the regulation of inflammatory cytokine release (Linger et al, 2008). Additionally, the TAM family has been linked to coagulopathy and cancer when altered experimentally or genetically (Linger et al, 2008). Tri-phosphorylation of MerTK at tyr749, tyr753 and tyr754 has been identified as a key target in platelet aggregation for developing a new anti-platelet drug that decreases bleeding complications, which are current side effects of similar drugs on the market today (Zhang et al, 2013). MerTK is also seen as a therapeutic target for treating lymphoblastic leukemias, melanoma, breast, lung, colon, liver, gastric, kidney, ovarian, uterine and brain cancers (Graham et al, 1994). There has recently been increased interest in synthesizing novel ATP-competitive small molecule tyrosine kinase inhibitors to decrease tri-phosphorylation of MerTK at tyr749, tyr753, and tyr754 as a therapeutic target to treat AML (Lee-Sherick et al, 2013).
Antigen Affinity Purified from Pooled Serum
Synthetic phospho-peptide corresponding to amino acid residues surrounding human MerTK Tyr749/753/754 conjugated to KLH
Human, Mouse, Rat
100 µl in 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol.
For research use only. Not intended for therapeutic or diagnostic use. Use of all products is subject to our terms and conditions, which can be viewed on our website.
After date of receipt, stable for at least 1 year at -20°C.